EllumGet notified

KLOW blend: what's in it

By Ellum EditorialUpdated AI use

The short answer

KLOW blend combines GHK-Cu, BPC-157, TB-500 and KPV.

The parts

  • GHK-Cu (injectable) Index

    Not FDA-approved

  • BPC-157 Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S0

    Papers on animals103
    Lab-dish (cell) papers1
    Papers PubMed tags as about people55
    Registered trials (ClinicalTrials.gov)2 of 3 search results name BPC-157
    Randomized trials in peoplenone found

  • TB-500 (thymosin beta-4 fragment LKKTETQ) Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S2.3

  • KPV Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.

Regulatory status by component

Not FDA-approved How we label status

  • As of October 4, 2026, GHK-Cu (injectable) is not FDA-approved for any use and is not on FDA's 503A bulks list. See GHK-Cu (injectable) in the Index →
  • As of October 4, 2026, BPC-157 is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See BPC-157 in the Index →
  • As of October 4, 2026, TB-500 (thymosin beta-4 fragment LKKTETQ) is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See TB-500 (thymosin beta-4 fragment LKKTETQ) in the Index →
  • As of October 4, 2026, KPV is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See KPV in the Index →

Status as of October 4, 2026

As a combination
Contains GHK-Cu injectable (no category; withdrawn 2026-04-22)
  • GHK-Cu (injectable): as of October 4, 2026 · source
  • BPC-157: as of October 4, 2026 · source
  • TB-500 (thymosin beta-4 fragment LKKTETQ): as of October 4, 2026 · source
  • KPV: as of October 4, 2026 · source

Get updates on KLOW blend

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: KLOW blend (1 selected) · edit
Peptides you're interested in
What we may email you about
More options (optional): research, doctor contact, paid offers

The research on KLOW blend

Key facts

Also known as: klow peptide, klow stack

Parts
GHK-Cu (injectable), BPC-157, TB-500 (thymosin beta-4 fragment LKKTETQ) and KPV
Route
injectable

References

Status sources

Sources as of October 4, 2026

  1. FDA: www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. FDA: www.fda.gov/media/94155/download
  3. WADA: www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

What this doesn’t establish

Results for one compound don't tell you what the four do together.